Carbendazim

Carbendazim (Mercarzole, Carbendazole) is a broad-spectrum systemic antimycotic and can be used to control a broad range of diseases on field crops, fruits, and vegetables, including sclerotinia rot of canola, wheat head blight, peanut leaf spot, and SB on rice. Its mode of action is to inhibit the formation of mitotic microtubules in of fungi.

Product information

CAS Number: 10605-21-7

Molecular Weight: 191.19

Formula: C9H9N3O2

Chemical Name: methyl N-(1H-1,3-benzodiazol-2-yl)carbamate

Smiles: COC(=O)NC1NC2=CC=CC=C2N=1

InChiKey: TWFZGCMQGLPBSX-UHFFFAOYSA-N

InChi: InChI=1S/C9H9N3O2/c1-14-9(13)12-8-10-6-4-2-3-5-7(6)11-8/h2-5H,1H3,(H2,10,11,12,13)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Solubility (25°C). 17 mg/mL(88.91 mM). Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Carbendazim (methyl 2-benzimidazolecarbamate) is widely used as a systemic fungicide in human food production and appears to act on fungal tubulin. However, it also inhibits proliferation of human cancer cells, including drug- and multidrug-resistant and p53-deficient cell lines, including murine melanoma, human breast, ovarian, lung, leukemia, and colon carcinoma cell lines, arresting the cells at the G2/M phase of the cell cycle and inducing apoptosis. It inhibits the proliferation of MCF7 human breast cancer cells with IC50 of 10 μM and arrests mitosis at a similar concentration (8 μM), in concert with suppression of microtubule dynamic instability without appreciable microtubule depolymerization. With microtubules assembled in vitro from pure tubulin, carbendazim also suppresses dynamic instability, reducing the dynamicity by 50% at 10 μM, with only minimal (21%) reduction of polymer mass. Carbendazim binds to mammalian tubulin (Kd, 42.8 ± 4.0 μM).

In Vivo:

Carbendazim (CBZ) is active in vivo against human pancreatic, lung, prostate, colon, and breast tumor xenografts. Oral administrations with CBZ at 100 and 500 mg/kg body weight for 28 days induces hepatic lipid metabolism disorder which is characterized by significant increases of hepatic lipid accumulation and triglyceride (TG) levels in mice. The serum cholesterol (TC), high-density lipoprotein, and low-density lipoprotein levels also increase after CBZ exposure. CBZ may also induce the occuring of inflammation characterized by the increase of serum IL-1β and IL-6 levels.

References:

1. Yuanxiang Jin, et al. Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. Toxicol Sci. 2015 Sep;147(1):116-26
2. Bilge G. Tuna, et al. Enhanced antitumor activity of carbendazim on HeLa cervical cancer cells by aptamer mediated controlled release. RSC Advances

Products are for research use only. Not for human use.